Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 115 Breast Neoplasms 113 Ovarian Neoplasms 71 Triple Negative Breast Neoplasms 56 Fallopian Tube Neoplasms 42 Endometrial Neoplasms 42 Squamous Cell Carcinoma of Head and Neck 39 Lung Neoplasms 38 Neoplasm Metastasis 35 Stomach Neoplasms 28 Neoplasms 28 Parkinson Disease 4, Autosomal Dominant Lewy Body 27 Esophageal Neoplasms 22 Esophageal Squamous Cell Carcinoma 21 Head and Neck Neoplasms 16 Carcinoma 16 Uterine Cervical Neoplasms 15 Carcinoma, Ovarian Epithelial 15 Colorectal Neoplasms 14 Carcinoma, Squamous Cell 11 Adenocarcinoma 10 Small Cell Lung Carcinoma 9 Adenocarcinoma Of Esophagus 9 Peritoneal Neoplasms 8 Oropharyngeal Neoplasms 8 Melanoma 8 Carcinoma, Transitional Cell 8 Urinary Bladder Neoplasms 7 Pancreatic Neoplasms 7 Mouth Neoplasms 7

Interventions

afuresertib 1 Paclitaxel 1 Gemcitabine 1 ALT-803 1 1-dodecylpyridoxal 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Platinum-resistant Ovarian Cancer × Paclitaxel × 1 year × Clear all

NCT04374630 2025-09-10

PROFECTA-II

Laekna Limited

Phase 2 Completed

Platinum-resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡